Genetic variants in a protein called NBCn2 have been tied to epilepsy and autism spectrum disorder for years. Researchers at the Icahn School of Medicine at Mount Sinai now have both, and their first inhibitors of the protein are already reducing neuronal activity in the dish. In primary neuronal culture and in brain slices, the compounds reduced neuronal activity, which is the direction you would want from a candidate for disorders of excessive firing. They reduced neuronal activity in primary culture and brain slices. Potentially, people with epilepsy and other conditions involving excessive neuronal activity, though no therapeutic claim is supported by this study.